Jay Zises serves as the chairman of A Cap, Inc., the investment management firm he established in 1991 in New York City. He assists a roster of high-net-worth clients in identifying emerging opportunities, particularly in companies started by innovative younger entrepreneurs with sound knowledge of their markets. In connection with this work, Jay Zises maintains a strong interest in investing in companies focused on synthetic biology. The field of synthetic biology involves the re-engineering of organic systems, or the creation of entirely new biological systems or components, in order to be of greater use to humanity. Applications for synthetic biology products include enhanced biofuels, synthesis of DNA, and the development of alternative energy sources. Some experts in the economics of the field estimated that, within the current decade, the market value of synthetic biology will reach more than $25 billion. This estimate is based on the growing demand for high-performing drug and vaccine products on the part of consumers and medical professionals. Another study of the market came up with a valuation of close to $40 billion by the year 2020.
0 Comments
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2019
CategoriesAll Community Outreach Education Finance Jay Zises Science Technology University Yeshiva University |